pfizer glp-1 drug ADA '26: Lilly's dominance, Pfizer's 'foundational' and Roche's 'me-too' option Sciwind Biosciences partners with Pfizer
Description
Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors
Even more concerning
See how GLP-1s are reshaping diabetes & obesity care.
Policy and Global Health Policy advances in 2025 laid critical groundwork for the next phase of obesity care
